- Home
- / Neos Therapeutics
Neos Therapeutics
Stock Price
$1.1
2021-03-25
Market Capitalization
$57.2 M
2021-03-25
Revenue
$64.6 M
FY, 2019
Neos Therapeutics Summary
Company Summary
- Overview
- Neos Therapeutics is a pharmaceutical company developing, manufacturing, and commercializing central nervous system-focused products. Its products are extended-release medications in patient-friendly, orally disintegrating tablet or oral suspension dosage forms developed for the treatment of attention deficit hyperactivity disorder (ADHD). The company merged with Aytu BioScience to form Aytu BioPharma.
- Type
- Public
- Status
- Closed
- Founded
- 2008
- HQ
- Grand Prairie, TX, US | view all locations
- Website
- http://www.neostx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Greg Pyszczymuka, Chief Commercial Officer
Nathaniel Massari, Executive Vice President, Rare Disease Operations
Russ McMahen, Senior Vice President of Research and Development
LocationsView all
2 locations detected
Grand Prairie, TX HQ
United States
2940 N Hwy 360
Blue Bell, PA
United States
1787 Sentry Pkwy W Building 18, Suite 120
Neos Therapeutics Financials
Summary Financials
- Revenue (Q3, 2020)
- $12.5M
- Gross profit (Q3, 2020)
- $7.4M
- Net income (Q3, 2020)
- ($4.9M)
- Cash (Q3, 2020)
- $12.7M
- EBIT (Q3, 2020)
- ($2.9M)
- Enterprise value
- $88.4M